InSightec

Overview
Activities
News

Insightec developed the Exablate Prime platform, which uses MRI-guided focused ultrasound for incisionless neurosurgery to treat essential tremor and Parkinson's disease. The company received FDA approval for treating advanced Parkinson's disease in 2021. In June 2024, Insightec raised USD 150 million to expand its incisionless neurosurgery treatments and invest in new indications. With over 160 systems installed worldwide, Insightec's technology has been used in nearly 20,000 commercial applications.

HQ Location:
Tirat Carmel ISR
Founded year:
1999
Employees:
251-500
Next-gen Medical Devices
Next-gen Medical Devices
Loading...
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.